Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
The new online Learning Center with new content can still be found under the “Training” folder on ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...